Newsletter | November 3, 2026

11.03.26 -- Transferring Analytical Methods In ADC Development

FOCUS ON OUTSOURCING

Transferring Analytical Methods In ADC Development

In this closing segment from the Bioprocess Online Live event “Ensuring Successful Technology Transfer In ADC Development,” panelists Sourav Kundu, Ph.D., and Will Olughu, Ph.D., discuss the transfer of analytical methods and importance of functionality assays in ADC development, as well as the traits of good CDMO partners.

Four Reasons You Should Choose Lyophilization For Your Next Project

Lyophilization ensures product stability, extends shelf life, supports sensitive formulations, and simplifies storage and transport, making it a critical choice for modern drug development projects.

Smarter Lead Selection And Faster Representative Material

Accelerate biologics development with earlier high-titer material, reduced CMC risk, and faster lead selection using transposase-based vectors and stable bulk pools.

Can A Single CDMO Manage Both Clinical And Commercial Biologics Supply?

Read about integrated clinical-to-commercial biologics manufacturing with scalable GMP capacity, centralized program management, and seamless technology continuity to reduce development risk.

5 Ways Pre-Filled Syringes Contribute To Better Patient Outcomes

In our series on pre-filled syringes, we explore five key ways this delivery format is enhancing patient outcomes, not just through the medicine it contains, but through the device design itself.

Why Cell And Gene CDMOs Benefit From Digitalization

Discover why digitization is crucial for cell and gene contract manufacturers by learning the various benefits digital transformation can offer such as efficiency, compliance, and innovation.

Supporting Late-Stage Drug Product Development

Meet us at CPHI Worldwide in Milan to gain insight into solutions for late-stage drug product development, manufacturing readiness, and CMC support.

Streamlining AAV And LVV Manufacturing Platform Solutions

Observe how streamlined, scalable platforms are transforming viral vector manufacturing to accelerate the delivery of cell and gene therapies to patients.

Developing Scalable, Global Solutions For Cell And Gene Manufacturing

Cell and gene therapies offer transformative potential for treating complex diseases, but their manufacturing and global delivery face significant challenges.

What Can You Do To Improve Your ADC's Chance Of Clinical Success?

Improving your ADC’s chance of clinical success requires an understanding of what potential obstacles lie ahead and what capabilities and expertise are necessary to overcome them.

The CDMO Pricing Playbook

Why do two CDMOs with identical direct costs quote prices 2.6x apart? Learn the three-element pricing framework, capacity utilization math, and market-based strategies that explain every RFQ surprise.

The Strategic Value Of In-House Delumping For Homogeneous API Production

API batch homogeneity supports efficient manufacturing. Controlled delumping improves powder flow and chargeability while maintaining particle size integrity and reducing GMP-scale risks.

OUTSOURCING SOLUTIONS

•

Accelerating Complex Injectable Programs - BE Biosol

•

June 2026 Capabilities Update: ADC - Simtra BioPharma Solutions

•

GMP Adventitious Virus Detection By NGS - Minaris

•

Manufacturing Life-Saving Gene Therapies - Andelyn Biosciences

•

Ensuring Quality Consistency: Global Commitment To Quality - Thermo Fisher Scientific

•

Wearable Injector - BD Medical - Pharmaceutical Systems

•

Tailored Support From Concept To Commercialization - Miltenyi Biotec

Connect With Bioprocess Online: